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were utilized to simulate a Cost-Effectiveness Acceptability Curve of each clinical 
area and type of intervention i.e. screening or vaccination program. Results: 
The cost-effectiveness function of prevention programs yield an ICER < € 30.000/
QALY in 80% of realizations. Vaccines are the most efficient interventions, since 
they exhibit an ICER lower than treatments of the same clinical in more than 90% 
of simulations ConClusions: Prevention programs typically require immedi-
ate investments yielding future health benefits. To acknowledge this peculiarity 
means to adopt not only a short (Vaccinations against influenza , chicken pox 
, measles), but also a medium (vaccination against zoster, genital warts , and 
tetanus) and long time horizon (screening of cancers and hepatitis) when assess-
ing the efficiency of healthcare programs. Failure to reach the threshold of 5 % 
of spending on prevention required by Italian national healthcare planning, is 
therefore to be understood as a form of rationing, rather than rationalization of 
healthcare resources.
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objeCtives: The Turkish Medicines and Medical Devices Agency (TMMDA) gives 
permission of unlicensed medicine use by patient basis. Authorized wholesalers 
including Turkish Pharmacists’ Association (TPA) can import the drugs based on 
the TMMDA’s permission. These medicines are reimbursed by the Social Security 
Institution (SSI), the main reimbursement agency in Turkey Until 2014 when 
wholesalers were also authorized, pharmaceuticals under this status could only 
be imported by the Turkish Pharmacists’ Association (TPA The aim of this study 
is to understand the trends in L subgroups (Antineoplastic and immunomodu-
lating agents) of ATC classification system unlicensed medicine consumption 
between 2011 and 2013 when the TPA was the only authorized supplier. Methods: 
Consumption data of L sub-group in the top 100 imported unlicensed medicines 
with the highest sales share in total expenses of imported off-label use was taken 
from the TMMDA computer database. L01, L02, L03 and L04 were taken as subgroups. 
Descriptive analysis was conducted. Results: The analysis showed that the L01 
had the highest percentage of active ingredients among L subgroups with 67% share 
in all L group medicines. The percentage of L01 rose from 67% to 76% between 2011 
and 2013. The consumption of L01 rose from 61 million TL to 230 million TL in the 
same period. L01 has the highest percentage of unit sales as well. ConClusions: 
The cost of imported medicines used in off-label use is increasing every year in 
Turkey. Some cost-containment measures (especially for L01-antineoplastic agents) 
should be taken to reduce the cost without risking patients’ access to innovative 
medicines.
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objeCtives: Medication errors are unintentional errors in how medicines are pre-
scribed, dispensed, administered, or monitored while controlled by a healthcare 
professional, patient, or consumer. Leendertse et al (2008) reported that 5.6% of 
acute hospital admissions are medication-related, of which 46.5% were poten-
tially preventable. This study estimated the costs related to medication errors 
that lead to avoidable hospitalizations in Belgium. Methods: Based on the inci-
dences from Leendertse et al (2008), the number of hospital admissions due to 
avoidable medication errors in Belgium was determined. The total avoidable costs 
attributable to medication errors was estimated, by multiplying the number of 
avoidable hospitalizations with the average cost of a hospital stay, calculated 
using the online official database of the Technical Cell (data from 2011). Costs 
were inflated to 2014. Results: The estimated average cost of a hospital stay in 
Belgium was € 4,886. Based on 2.6%, the incidence rate of total hospital admissions 
attributable to medication errors, 42,797 hospital admissions that could have been 
avoided due to medication errors were estimated. Avoiding these hospitaliza-
tions would produce potential savings of € 209Mn per year. ConClusions: This 
study shows that the economic and health burden of preventable medication 
errors is high. As such, a synergic approach is warranted nationally and across 
national borders. This should entail communication and involvement from all 
different stakeholders (medical doctors, pharmacists, hospitals, national and 
international pharmacovigilance organizations) in the provision and delivery 
of care.
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objeCtives: Prior to February 2013, price management within Astellas Pharma 
Europe Ltd. was done manually using an Excel database. The system was labour 
intensive, slow to update, and prone to error. We developed an innovative web-
based pricing information management system to address the shortcomings of the 
previous system. Methods: A secure web-based system for submitting, review-
ing and approving pricing requests was developed for use by 21 affiliates in 40 
countries in Europe, Middle East and Africa. The aims of the new system were 
to: (i) reduce time/effort to approve price change requests; (ii) reduce the risk of 
using incorrect/unapproved prices; (iii) improve the visibility of pricing data to 
affiliates; (iv) improve approval process compliance. The system was designed 
to: track all pricing applications and approval status; update approved pricing 
information automatically; provide fixed and customisable reports of pricing 
increase in the number of new chemical entities (NCEs) previously launched (1994-
2002) - had higher increase in mean age at death, controlling for the effects of 
macroeconomic trends and overall changes in the healthcare system. Results: 
The diseases for which more drugs were registered during the period 1994-2002 
had larger increases in mean age at death during 2002-2010. The increase in mean 
age at death for “high-innovation diseases” (mean number of NCE 1994-2002 = 
12.9) was 3.1 years, while 1.7 years for “low-innovation diseases” (mean number 
of NCE 1994-2002 = 3.9). Furthermore, our estimates indicate that about 1/3 of the 
total increase in longevity (i.e. 0.8 years) was due to NCE 1994-2002. Thus, phar-
maceutical innovation increased mean age at death by 1.2 months per year. There 
were 106,242 deaths in Portugal in 2010. Hence the number of life-years gained in 
2010 due to drugs registered during the period 1994-2002 was 84,994 (= 0.80 years * 
106,242 deaths). ConClusions: These findings demonstrate that pharmaceutical 
innovation brought significant health gains in Portugal in the past decade. Access to 
innovation is therefore crucial if society desires to mantain the positive momentum 
of longevity increase.
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objeCtives: Antibiotic use outside hospital in Belgium is known to be one of 
the highest in Europe. This has aside an impact on resistance also an important 
economic burden. The aim of this study was to evaluate the potential savings that 
could be realized in case prescription behavior in Belgium would be similar to the 
Netherlands, a country known for its strict antibiotic use. Methods: Current 
spending levels for antibiotics were determined in Belgium and the Netherlands. 
Volume and value sales were determined per country (average number of pills sold 
per capita) based on IMS Health Belgian National Retail Database available to IMS 
Health in both countries via the IMS MIDAS platform (2013 data). The potential 
country-level prescription cost in Belgium was estimated by multiplying aver-
age number of pills/person in the Netherlands, with the cost/pill in Belgium and 
extrapolating the result to the total population in Belgium, assuming that prescrib-
ing levels in Belgium were equal to those in the Netherlands and using Belgian 
prices. Also reasons for antibiotic use were checked in the IMS Longitudinal 
Patient Database. Results: In Belgium the number of pills per capita was sig-
nificantly higher compared to the Netherlands (12.66 vs. 5.93 pills/person). With 
a 30% smaller population than the Netherlands, spending in Belgium is 3 times 
higher. The estimated savings for the Belgian payer applying the usage (pill/per-
son) of the Netherlands and current cost/pill in Belgium were € 71.5 Mn. Reasons 
for antibiotics prescription in Belgium were mainly upper airway infections and 
bronchitis. ConClusions: By comparing Belgium’s prescription patterns to the 
Netherlands, we estimated important potential savings due to antibiotics mis-use/
over-use. The additional health and cost implications of antibiotics resistance 
were not taken into account. These savings could then be reinvested in covering 
innovative drugs.
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objeCtives: The aim of this study is to analyze the impact of multimorbidity on 
ambulatory pharmaceutical cost and hospital cost. We use Clinical Risk Groups 
(CRG) for determining the multimorbidity. CRG is a classification system for risk 
adjustment which assigns each individual to risk groups based on chronic condi-
tion. Methods: In a cross-sectional study we extracted the data of cost and co-
morbidity using CRGs from a data base of 156.811 people register with the health 
district of Denia, in eastern Spain, during 2013. Two OLS models were constructed for 
natural logarithm of the dependent variable of pharmaceutical and the other being 
hospital cost per patient respectively. Both models we take as independent variables 
the nine main health status of CRG. Results: The ambulatory pharmaceutical 
cost represents 27.00% of the total expenditure. The CRG with the highest related 
ambulatory costs was CRG 7 (Dominant chronic disease in 3 or more organ systems 
(38.77%)). The highest hospital costs were found to be in the groups of higher sever-
ity levels (8.Dominant and metastatic malignances and 9.Catastropihc conditions), 
being 80.86% and 85.23% respectively. The statistical analysis showed a higher level 
of significance in the ambulatory pharmaceutical cost model: R squared of 58.8% 
versus the 12.8% in the hospital model. ConClusions: There is wide variability 
in the percentage of outpatient expenditure between the different status levels of 
the CRG. The explanatory capacity of the CRG is much higher when it is outpatient 
cost because patients suffering with chronic conditions are regular users of the 
Primary Care than of Hospital Care.
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objeCtives: To review evidence on cost-effectiveness of screening and vaccina-
tion programs currently funded in Italy, in order to develop a tool to appraise the 
efficiency of healthcare expenditure on prevention. Methods: Cost-utility studies 
carried out in Italy between 1995 and 2014 where gathered though PubMed search 
engine. The following inclusion criteria were applied to the records retrieved: (i) 
Cost-Utility analysis; (ii) Italian setting; (iii) National Health Service Perspective; 
(iv) lifetime horizon; (v) intervention belonging to one of these clinical area: viral 
hepatitis, cancers, metabolic and cardiovascular diseases; infectious or respiratory 
disease. Prevention programs have been ordered in league tables. Mean and stand-
ard deviation of incremental values and ICERs reported in the selected studies 
